LLY Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In RESULTS: Q1, Q1 2027, Eli Lilly: Plans To Submit Biol
LLY Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In RESULTS: Q1, Q1 2027, Eli Lilly: Plans To Submit Biologics License Application For Retatrutide To FDA In Earnings Notes:, Reports positive topline results from triumph-2 & triumph-3, two pivotal phase 3 trials evaluating retatrutide,